Daming capsule combined with SGLT2i confers protection against diabetes with myocardial ischemia/reperfusion injury induced ferroptosis via AMPK

Figure 7 The combination therapy of Sodium-dependent glucose transporters 2 inhibitor combined with daming capsule relieved oxidative stress through adenosine monophosphate-activated protein kinase pathway to mitigate diabetes mellitus with ischemia-reperfusion effectively. A: Western blot was performed to detect the protein expression of phospho-adenosine monophosphate-activated protein kinase (p-AMPK) and adenosine monophosphate-activated protein kinase (AMPK) in mice; B: Western blot was performed to detect the protein expression of p-AMPK and AMPK in H9C2 cells. Above results are presented as the mean ± SD. The comparison between two groups was conducted by t-test. ^aP < 0.05 vs the wild type group or the control group; ^bP < 0.05 vs the diabetes mellitus + ischemia-reperfusion group or the high glucose + palmitic acid + hypoxia/reoxygenation group. WT: Wild type; DMC: Daming capsule; SGLT2i: Sodium-dependent glucose transporters 2 inhibitor; I/R: Ischemia-reperfusion; DM: Diabetes mellitus; HG: High glucose; PA: Palmitic acid; H/R: Hypoxia/reoxygenation; CTRL: Control.